Targeted Therapy in HR+ HER2− Metastatic Breast Cancer: Current Clinical Trials and Their Implications for CDK4/6 Inhibitor Therapy and beyond Treatment Options
1
Breast Surgery, Breast-Center Zurich, 8008 Zurich, Switzerland
2
Faculty of Medicine, University of Witten-Herdecke, 58455 Witten, Germany
3
Institute of Gynecology and Obstetrics, University Hospital Wuppertal, 42109 Wuppertal, Germany
*
Author to whom correspondence should be addressed.
Cancers 2021, 13(23), 5994; https://doi.org/10.3390/cancers13235994
Submission received: 9 November 2021
/
Revised: 26 November 2021
/
Accepted: 27 November 2021
/
Published: 29 November 2021
(This article belongs to the Special Issue Metastatic Breast Cancers)
Simple Summary
In the treatment of hormone-receptor positive, HER2 negative metastatic breast cancer, targeted therapy showed improved overall survival and it has become an established treatment within recent years. Some study results conflict with others. As multiple new research articles on this topic have been recently published, this review aims to crystallize the current relevant results.
Abstract
A metastatic state of breast cancer (MBC) affects hundreds of thousands of women worldwide. In hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) MBC, cyclin-dependent kinase (CDK)4/6 inhibitors can improve the progression-free survival (PFS), as well as the overall survival (OS), in selected patients and have been established as first- and second-line therapies. However, as MBC remains uncurable, resistance to CDK4/6 inhibitors occurs and requires alternative treatment approaches. Data on targeted therapy continue to mature, and the number of publications has been constantly rising. This review provides a summary and update on the clinical relevance, patient selection, ongoing trials of CDK4/6 inhibitors, and further targeted therapy options. It focuses on clinical aspects and practicability, as well as adverse events and patient-reported outcomes.
